Latest & greatest articles for pulmonary embolism

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on pulmonary embolism or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on pulmonary embolism and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for pulmonary embolism

301. Acute pulmonary embolism: cost-effectiveness analysis of the effect of artificial neural networks on patient care

Acute pulmonary embolism: cost-effectiveness analysis of the effect of artificial neural networks on patient care Acute pulmonary embolism: cost-effectiveness analysis of the effect of artificial neural networks on patient care Acute pulmonary embolism: cost-effectiveness analysis of the effect of artificial neural networks on patient care Tourassi G D, Floyd C E, Coleman R E Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED (...) . Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of an artificial neural network (ANN) to diagnose and determine treatment strategies in patients with suspected acute pulmonary embolism. The network was trained to predict the probability of pulmonary embolism by using physicians' findings from ventilation-perfusion lung scans and chest

NHS Economic Evaluation Database.1998

302. Economic evaluation comparing low molecular weight heparin with other modalities for the prevention of deep vein thrombosis and pulmonary embolism following total hip or knee arthroplasty

Economic evaluation comparing low molecular weight heparin with other modalities for the prevention of deep vein thrombosis and pulmonary embolism following total hip or knee arthroplasty Economic evaluation comparing low molecular weight heparin with other modalities for the prevention of deep vein thrombosis and pulmonary embolism following total hip or knee arthroplasty Economic evaluation comparing low molecular weight heparin with other modalities for the prevention of deep vein thrombosis (...) and pulmonary embolism following total hip or knee arthroplasty Anderson D R, O'Brien B, Nagpal S, et al Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Anderson D R, O'Brien B, Nagpal S, et al. Economic evaluation comparing low molecular weight heparin with other modalities for the prevention of deep vein thrombosis and pulmonary embolism following

Health Technology Assessment (HTA) Database.1998

303. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prévention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group.

A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prévention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group. 9459643 1998 02 12 1998 02 12 2006 11 15 0028-4793 338 7 1998 Feb 12 The New England journal of medicine N. Engl. J. Med. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prévention du Risque d'Embolie Pulmonaire par (...) Interruption Cave Study Group. 409-15 The efficacy and safety of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis is still a matter of debate. Using a two-by-two factorial design, we randomly assigned 400 patients with proximal deep-vein thrombosis who were at risk for pulmonary embolism to receive a vena caval filter (200 patients) or no filter (200 patients), and to receive low-molecular-weight heparin (enoxaparin, 195 patients) or unfractionated

NEJM1998

304. Economic evaluation of the use of nadroparin calcium in the prophylaxis of deep vein thrombosis and pulmonary embolism in surgical patients in Italy

Economic evaluation of the use of nadroparin calcium in the prophylaxis of deep vein thrombosis and pulmonary embolism in surgical patients in Italy Economic evaluation of the use of nadroparin calcium in the prophylaxis of deep vein thrombosis and pulmonary embolism in surgical patients in Italy Economic evaluation of the use of nadroparin calcium in the prophylaxis of deep vein thrombosis and pulmonary embolism in surgical patients in Italy Lloyd A, Aitken J A, Hoffmeyer U K, Kelso E J (...) , Wakerly E C, Barber N D Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of nadroparin calcium (a low-molecular weight heparin (LMWH)) in the prophylaxis of deep vein thrombosis (DVT) and pulmonary embolism (PE). Type

NHS Economic Evaluation Database.1997

305. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group. Tinzaparine ou Heparine Standard: Evaluations dans l'Embolie Pulmonaire.

A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group. Tinzaparine ou Heparine Standard: Evaluations dans l'Embolie Pulmonaire. 9278462 1997 09 04 1997 09 04 2016 11 24 0028-4793 337 10 1997 Sep 04 The New England journal of medicine N. Engl. J. Med. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group. Tinzaparine ou Heparine Standard: Evaluations (...) dans l'Embolie Pulmonaire. 663-9 Low-molecular-weight heparin appears to be at least as effective and safe as standard, unfractionated heparin for the treatment of deep-vein thrombosis, but only limited data are available on the use of low-molecular-weight heparin to treat acute symptomatic pulmonary embolism. We randomly assigned 612 patients with symptomatic pulmonary embolism who did not require thrombolytic therapy or embolectomy to either subcutaneous low-molecular-weight heparin (tinzaparin

NEJM1997

306. Ultrasound at scintigraphic intermediate probability of pulmonary embolism

Ultrasound at scintigraphic intermediate probability of pulmonary embolism Ultrasound at scintigraphic intermediate probability of pulmonary embolism Ultrasound at scintigraphic intermediate probability of pulmonary embolism Christiansen F, Kellerth T, Andersson T, Ragnarsson A, Hjortevang F Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions (...) followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Ultrasound as an additional diagnostic examination to 'intermediate probability of pulmonary embolism (PE)' established by ventilation/perfusion(V/Q) scintigraphy. Type of intervention Secondary prevention; diagnosis. Economic study type Cost-effectiveness analysis. Study population Patients aged 18 years or older with a diagnosis of "intermediate probability of PE" according

NHS Economic Evaluation Database.1996

307. Spiral CT angiography for suspected pulmonary embolism: a cost-effectiveness analysis

Spiral CT angiography for suspected pulmonary embolism: a cost-effectiveness analysis Spiral CT angiography for suspected pulmonary embolism: a cost-effectiveness analysis Spiral CT angiography for suspected pulmonary embolism: a cost-effectiveness analysis van Erkel A R, van Rossum A B, Bloem J L, Klevit J, Pattynama P M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods (...) , the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Spiral computed tomographic (CT) angiography and conventional pulmonary angiography. Type of intervention Diagnosis. Economic study type Cost-effectiveness analysis. Study population Persons with suspected PE. Setting The setting was Leiden University Hospital, The Netherlands. Dates to which data relate Effectiveness data were collected from studies published

NHS Economic Evaluation Database.1996

308. The cost-effectiveness of diagnostic strategies in patients with suspected pulmonary embolism

The cost-effectiveness of diagnostic strategies in patients with suspected pulmonary embolism The cost-effectiveness of diagnostic strategies in patients with suspected pulmonary embolism The cost-effectiveness of diagnostic strategies in patients with suspected pulmonary embolism Michel B C, Seerden R J, Rutten F F, Van Beek E J, Buller H R Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief (...) summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Diagnostic strategy (and anticoagulant treatment in case of diagnosis of pulmonary embolism) recommended by the Dutch consensus meeting in 1992 consisting of ventilation-perfusion (VQ) scan followed by ultrasound of lower extremity, followed by lung angiography. Comparison strategies also may include a D-dimer test (marker of clot

NHS Economic Evaluation Database.1996

309. The role of plasma D-dimer concentration in the exclusion of pulmonary embolism

The role of plasma D-dimer concentration in the exclusion of pulmonary embolism The role of plasma D-dimer concentration in the exclusion of pulmonary embolism The role of plasma D-dimer concentration in the exclusion of pulmonary embolism van Beek E J, Schenk B E, Michel B C, van den Ende B, Brandjes D P, van der Heide Y T, Bossuyt P M, Buller H R Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief (...) summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Plasma D-dimer concentration in the exclusion of pulmonary embolism. Type of intervention Diagnosis. Economic study type Cost-effectiveness analysis. Study population Consecutive patients (both in- and outpatients) who underwent diagnostic work-up for clinically suspected pulmonary embolism. Setting The practice setting was two

NHS Economic Evaluation Database.1996

310. Randomised, controlled trial of low-dose heparin for prevention of fatal pulmonary embolism in patients with infectious diseases. The Heparin Prophylaxis Study Group.

Randomised, controlled trial of low-dose heparin for prevention of fatal pulmonary embolism in patients with infectious diseases. The Heparin Prophylaxis Study Group. 8637340 1996 07 05 1996 07 05 2015 06 16 0140-6736 347 9012 1996 May 18 Lancet (London, England) Lancet Randomised, controlled trial of low-dose heparin for prevention of fatal pulmonary embolism in patients with infectious diseases. The Heparin Prophylaxis Study Group. 1357-61 Fatal pulmonary embolism and other thromboembolic (...) complications are common in hospital inpatients. However, there is little evidence on the routine use of pharmacological thromboprophylaxis in non-surgical patients. We assessed the efficacy and safety of low-dose heparin in the prevention of hospital-acquired, clinically relevant, fatal pulmonary embolism in patients with infectious diseases. Our study used the postrandomisation consent design. 19,751 consecutive patients, aged 55 years or older, admitted to departments of infectious diseases in six

Lancet1996

311. Collaborative overview of randomised trials of antiplatelet therapy - III: reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients

Collaborative overview of randomised trials of antiplatelet therapy - III: reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients Collaborative overview of randomised trials of antiplatelet therapy - III: reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients Collaborative overview of randomised trials of antiplatelet therapy - III: reduction in venous thrombosis (...) and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients Antiplatelet Trialists' Collaboration Authors' objectives To determine the efficacy of antiplatelet therapy as prophylaxis against deep venous thrombosis or pulmonary embolism in surgical and high-risk medical patients. Searching MEDLINE and Current Contents were searched by computer, and journals were manually searched. Additional material was obtained by examining reference lists of trials, review articles, abstracts

DARE.1994

312. Alteplase versus heparin in acute pulmonary embolism: randomised trial assessing right-ventricular function and pulmonary perfusion.

Alteplase versus heparin in acute pulmonary embolism: randomised trial assessing right-ventricular function and pulmonary perfusion. 8094768 1993 03 25 1993 03 25 2016 11 23 0140-6736 341 8844 1993 Feb 27 Lancet (London, England) Lancet Alteplase versus heparin in acute pulmonary embolism: randomised trial assessing right-ventricular function and pulmonary perfusion. 507-11 Data from a non-randomised study have hinted that in patients with acute pulmonary embolism (PE), thrombolysis followed (...) %). No clinical episodes of recurrent PE were noted among rt-PA patients, but there were 2 fatal and 3 non-fatal clinically suspected recurrent PEs within 14 days in patients randomised to heparin alone. rt-PA rapidly improves right-ventricular function and pulmonary perfusion among patients with PE and may lead to a lower rate of adverse clinical outcomes. Goldhaber S Z SZ Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts 02115. Haire W D WD Feldstein M L ML Miller M M Toltzis R R

Lancet1993

313. Optimum duration of anticoagulation for deep-vein thrombosis and pulmonary embolism. Research Committee of the British Thoracic Society.

Optimum duration of anticoagulation for deep-vein thrombosis and pulmonary embolism. Research Committee of the British Thoracic Society. 1357297 1992 11 02 1992 11 02 2015 06 16 0140-6736 340 8824 1992 Oct 10 Lancet (London, England) Lancet Optimum duration of anticoagulation for deep-vein thrombosis and pulmonary embolism. Research Committee of the British Thoracic Society. 873-6 The optimum duration of anticoagulation therapy for deep-vein thrombosis (DVT) and pulmonary embolism (PE) is (...) not clear. We have carried out a multicentre comparison of 4 weeks' and 3 months' anticoagulation in patients admitted to hospital with acute DVT, PE, or both. Of 712 patients enrolled, 358 were assigned 4 weeks' treatment and 354 3 months'. Objective confirmation of the diagnosis was obtained in 71%. PE caused or contributed to death in 7 patients (3 treated for 4 weeks, 4 for 3 months). Adverse effects were uncommon, although 1 patient (4-week group) died of haemorrhage. The numbers of patients whose

Lancet1992

314. Randomised controlled trial of recombinant tissue plasminogen activator versus urokinase in the treatment of acute pulmonary embolism.

Randomised controlled trial of recombinant tissue plasminogen activator versus urokinase in the treatment of acute pulmonary embolism. 2899718 1988 09 02 1988 09 02 2016 11 23 0140-6736 2 8606 1988 Aug 06 Lancet (London, England) Lancet Randomised controlled trial of recombinant tissue plasminogen activator versus urokinase in the treatment of acute pulmonary embolism. 293-8 The effect of intravenous recombinant human tissue-type plasminogen activator (rt-PA) was compared with that of urokinase (...) in 45 patients with angiographically documented pulmonary embolism (PE) in a randomised controlled trial. The two principal end-points were clot lysis at 2 h, as assessed by angiography, and pulmonary reperfusion at 24 h, as assessed by perfusion lung scanning. All patients received the full dose of rt-PA but urokinase infusions were terminated prematurely (on average after 18 h) in 9 patients because of allergy in 1 and uncontrollable bleeding in 8. By 2 h, 82% of rt-PA-treated patients showed clot

Lancet1988

315. Safety and efficacy of warfarin started early after submassive venous thrombosis or pulmonary embolism.

Safety and efficacy of warfarin started early after submassive venous thrombosis or pulmonary embolism. 2878173 1987 01 06 1987 01 06 2015 06 16 0140-6736 2 8519 1986 Dec 06 Lancet (London, England) Lancet Safety and efficacy of warfarin started early after submassive venous thrombosis or pulmonary embolism. 1293-6 Two anticoagulant regimens, similar except for the timing of warfarin therapy, were compared in patients with clinically submassive venous thromboembolism (VTE). Warfarin was begun (...) Trial Research Support, Non-U.S. Gov't England Lancet 2985213R 0140-6736 5Q7ZVV76EI Warfarin 9005-49-6 Heparin AIM IM Aged Clinical Trials as Topic Heparin therapeutic use Humans Middle Aged Pulmonary Embolism drug therapy mortality Random Allocation Recurrence Thrombophlebitis drug therapy mortality Time Factors Warfarin administration & dosage therapeutic use 1986 12 6 1986 12 6 0 1 1986 12 6 0 0 ppublish 2878173 S0140-6736(86)91431-5

Lancet1986

316. Effect of thrombolytic therapy on pulmonary-capillary blood volume in patients with pulmonary embolism.

Effect of thrombolytic therapy on pulmonary-capillary blood volume in patients with pulmonary embolism. 7412801 1980 11 24 1980 11 24 2008 11 21 0028-4793 303 15 1980 Oct 09 The New England journal of medicine N. Engl. J. Med. Effect of thrombolytic therapy on pulmonary-capillary blood volume in patients with pulmonary embolism. 842-5 To compare the effects of heparin thrombolytic agents in pulmonary thromboembolic disease, we randomly assigned 40 patients with pulmonary emboli but without (...) pharmacology Humans Pulmonary Circulation drug effects Pulmonary Diffusing Capacity Pulmonary Embolism drug therapy physiopathology Streptokinase pharmacology Urokinase-Type Plasminogen Activator pharmacology 1980 10 9 1980 10 9 0 1 1980 10 9 0 0 ppublish 7412801 10.1056/NEJM198010093031502

NEJM1980

317. Prophylaxis against postoperative pulmonary embolism and deep-vein thrombosis by low-dose heparin.

Prophylaxis against postoperative pulmonary embolism and deep-vein thrombosis by low-dose heparin. 77413 1978 07 24 1978 07 24 2015 06 16 0140-6736 1 8074 1978 May 27 Lancet (London, England) Lancet Prophylaxis against postoperative pulmonary embolism and deep-vein thrombosis by low-dose heparin. 1115-6 The prophylactic effect of low-dose heparin on postoperative fatal and on clinically apparent but non-fatal thromboembolic complications was studied in a double-blind, prospective, randomised (...) blood supply Male Middle Aged Pelvis blood supply Placebos Postoperative Complications prevention & control Prospective Studies Pulmonary Embolism prevention & control Research Design Thrombophlebitis prevention & control 785501 00083857 A double-blind prospective study was conducted on 1296 patients who had undergone surgery, to observe the effects of low-dose heparin on postoperative fatal and nonfatal thromboembolic complications. 16 patients out of 652 in the placebo group had such complications

Lancet1978

318. Prevention of Fatal Postoperative pulmonary embolism by low doses of heparin. Reappraisal of results of international multicentre trial.

Prevention of Fatal Postoperative pulmonary embolism by low doses of heparin. Reappraisal of results of international multicentre trial. 65660 1977 04 25 1977 04 25 2015 06 16 0140-6736 1 8011 1977 Mar 12 Lancet (London, England) Lancet Prevention of Fatal Postoperative pulmonary embolism by low doses of heparin. Reappraisal of results of international multicentre trial. 567-9 The results of a multicentre trial, designed to assess the efficacy of low-dose heparin in preventing fatal (...) postoperative pulmonary embolism, were published in July 1975. In view of inconsistencies which have now become apparent in the data from one of the twenty-eight centres which took part in the trial, the results of the trial have been re-examined, excluding the data from this centre. Of 4031 patients remaining after exclusion of these data, 2033 were in the control group and 1998 in the heparin group. 170 (4-2%) patients died during the postoperative period, 94 in the control group and 76 in the heparin

Lancet1977

319. Warfarin sodium in prevention of deep venous thrombosis and pulmonary embolism in patients with fractured neck of femur.

Warfarin sodium in prevention of deep venous thrombosis and pulmonary embolism in patients with fractured neck of femur. 62111 1976 12 30 1976 12 30 2015 06 16 0140-6736 2 7991 1976 Oct 23 Lancet (London, England) Lancet Warfarin sodium in prevention of deep venous thrombosis and pulmonary embolism in patients with fractured neck of femur. 869-72 In a prospective controlled randomised trial, the prophylactic value of warfarin sodium (in doses aimed at maintaining a "Thrombotest" value of 10 (...) % and given from the day of admission until independent mobility had been achieved or for 3 mo, whichever was the sooner) was assessed in 160 elderly patients who had sustained a fracture of the femoral neck. Treatment significantly reduced the frequency of deep venous thrombosis (D.V.T.), whether indicated by the 125I-fibrinogen test during life or assessed by detailed post-mortem studies. Pulmonary embolism was eliminated in treated patients, but the difference in mortality between the treatment

Lancet1976

320. Prevention of fatal postoperative pulmonary embolism by low doses of heparin. An international multicentre trial.

Prevention of fatal postoperative pulmonary embolism by low doses of heparin. An international multicentre trial. 49649 1975 09 18 1975 09 18 2015 06 16 0140-6736 2 7924 1975 Jul 12 Lancet (London, England) Lancet Prevention of fatal postoperative pulmonary embolism by low doses of heparin. An international multicentre trial. 45-51 The efficacy of low-dose heparin in preventing fatal postoperative pulmonary embolism has been investigated in a multicentre prospective randomised trial. 4121 (...) % in the heparin group had necropsy examination. 16 patients in the control group and 2 in the heparin group were found at necropsy to have died due to acute massive pulmonary embolism (P smaller than 0-005). In addition, emboli found at necropsy in 6 patients in the control group and 3 in the heparin group were considered either contributory to death or an incidental finding since death in these patients was attributed to other causes. Taking all pulmonary emboli together, the findings were again significant

Lancet1975